Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity

Antinori, 2017, Chagas disease in Europe: a review for the internist in the globalized world, Eur. J. Intern. Med., 43, 6, 10.1016/j.ejim.2017.05.001 Borst, 1995, New mechanisms of drug resistance in parasitic protozoa, Annu. Rev. Microbiol., 49, 427, 10.1146/annurev.mi.49.100195.002235 Buckner, 2003, Cloning and analysis of Trypanosoma cruzi lanosterol 14α-demethylase, Mol. Biochem. Parasitol., 132, 75, 10.1016/j.molbiopara.2003.07.004 Buckner, 1998, Induction of resistance to azole drugs in Trypanosoma cruzi, Antimicrob. Agents Chemother., 42, 3245, 10.1128/AAC.42.12.3245 Camargo, 1964, Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosomes in liquid media, Rev. Inst. Med. Trop. Sao Paulo, 93 Campos, 2017, Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole, Sci. Rep., 7, 14407, 10.1038/s41598-017-14986-6 Campos, 2014, Benznidazole-resistance in Trypanosoma cruzi: evidence that distinct mechanisms can act in concert, Mol. Biochem. Parasitol., 193, 17, 10.1016/j.molbiopara.2014.01.002 Cencig, 2011, Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome, PLoS Neglected Trop. Dis., 5, e1216, 10.1371/journal.pntd.0001216 Chen, 2020, Uncovering new mutations conferring azole resistance in the Aspergillus fumigatus cyp51A gene, Front. Microbiol., 10, 3127, 10.3389/fmicb.2019.03127 Cherkesova, 2014, Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibition, FEBS Lett., 588, 3878, 10.1016/j.febslet.2014.08.030 Clemons, 2017, Lack of efficacy of liposomal amphotericin B against acute and chronic Trypanosoma cruzi infection in mice, Am. J. Trop. Med. Hyg., 97, 1141, 10.4269/ajtmh.16-0975 Daniels, 2010, Cell biology of the trypanosome genome, Microbiol. Mol. Biol. Rev., 74, 552, 10.1128/MMBR.00024-10 De-Castro, 1993, Differential effect of amphotericin B on the three evolutive stages of Trypanosoma cruzi and on the host cell-parasite interaction, Braz. J. Med. Biol. Res., 26, 1219 Di Noia, 2002, A Trypanosoma cruzi small surface molecule provides the first immunological evidence that Chagas' disease is due to a single parasite lineage, J. Exp. Med., 195, 401, 10.1084/jem.20011433 El-Sayed, 2005, The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease, Science, 309, 409, 10.1126/science.1112631 Filardi, 1987, Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease, Trans. R. Soc. Trop. Med. Hyg., 81, 755, 10.1016/0035-9203(87)90020-4 Francisco, 2015, Limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging, Antimicrob. Agents Chemother., 59, 4653, 10.1128/AAC.00520-15 Franco, 2019, Drug discovery for Chagas disease: impact of different host cell lines on assay performance and hit compound selection, Trav. Med. Infect. Dis., 4, 82 Franzén, 2011, Shotgun sequencing analysis of Trypanosoma cruzi I Sylvio X10/1 and comparison with T. cruzi VI CL Brener, PLoS Neglected Trop. Dis., 5, e984, 10.1371/journal.pntd.0000984 Goad, 1989, The activity of ketoconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitro, Mol. Biochem. Parasitol., 32, 179, 10.1016/0166-6851(89)90069-8 Gotoh, 1992, Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences, J. Biol. Chem., 267, 83, 10.1016/S0021-9258(18)48462-1 Grisard, 2014, Trypanosoma cruzi clone Dm28c draft genome sequence, Genome Announc., 2, 10.1128/genomeA.01114-13 Gulin, 2013, Efficacy of voriconazole in a murine model of acute Trypanosoma cruzi infection, J. Antimicrob. Chemother., 68, 888, 10.1093/jac/dks478 Haido, 1989, Amphotericin B-induced damage of Trypanosoma cruzi epimastigotes, Chem. Biol. Interact., 71, 91, 10.1016/0009-2797(89)90092-6 Hall, 1999, BioEdit: a user friendly biological sequence alignment editor and analysis program for Windows 95/98/NT, Nucleic Acids Symp. Ser., 41, 95 Hargrove, 2017, Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis, J. Biol. Chem., 292, 6728, 10.1074/jbc.M117.778308 Hargrove, 2013, Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity, J. Biol. Chem., 288, 31602, 10.1074/jbc.M113.497990 Herman, 2014, A genomic and evolutionary approach reveals non-genetic drug resistance in malaria, Genome Biol., 15, 511, 10.1186/s13059-014-0511-2 Keenan, 2012, Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease, J. Med. Chem., 55, 4189, 10.1021/jm2015809 Khare, 2015, Antitrypanosomal treatment with benznidazole is superior to posaconazole regimens in mouse models of Chagas disease, Antimicrob. Agents Chemother., 59, 6385, 10.1128/AAC.00689-15 Kovacs, 2006, Determination of intrinsic hydrophilicity/hydrophobicity of amino acid side chains in peptides in the absence of nearest-neighbor or conformational effects, Biopolymers, 84, 283, 10.1002/bip.20417 Lee, 2013, Global economic burden of Chagas disease: a computational simulation model, Lancet Infect. Dis., 13, 342, 10.1016/S1473-3099(13)70002-1 Lepesheva, 2010, Crystal structures of Trypanosoma brucei sterol 14α-demethylase and implications for selective treatment of human infections, J. Biol. Chem., 285, 1773, 10.1074/jbc.M109.067470 Lepesheva, 2011, Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis, Curr. Top. Med. Chem., 11, 2060, 10.2174/156802611796575902 Lepesheva, 2007, Sterol 14α-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms, Biochim. Biophys. Acta Gen. Subj., 1770, 467, 10.1016/j.bbagen.2006.07.018 Lepesheva, 2006, CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B’ helix defines substrate preferences of sterol 14α-demethylase, J. Biol. Chem., 281, 3577, 10.1074/jbc.M510317200 Lewis, 2009, Genotyping of Trypanosoma cruzi: systematic selection of assays allowing rapid and accurate discrimination of all known lineages, Am. J. Trop. Med. Hyg., 81, 1041, 10.4269/ajtmh.2009.09-0305 McCabe, 1986, In vitro and in vivo effects of itraconazole against Trypanosoma cruzi, Am. J. Trop. Med. Hyg., 35, 280, 10.4269/ajtmh.1986.35.280 Molina, 2014, Randomized trial of posaconazole and benznidazole for chronic Chagas' disease, N. Engl. J. Med., 370, 1899, 10.1056/NEJMoa1313122 Moraes, 2016, Novel drug discovery for Chagas disease, Expet Opin. Drug Discov., 11, 447, 10.1517/17460441.2016.1160883 Moraes, 2014, Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development, Sci. Rep., 4, 4703, 10.1038/srep04703 Morillo, 2015, Randomized trial of benznidazole for chronic Chagas' cardiomyopathy, N. Engl. J. Med., 373, 1295, 10.1056/NEJMoa1507574 Morillo, 2017, Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS trial, J. Am. Coll. Cardiol., 69, 939, 10.1016/j.jacc.2016.12.023 Oguike, 2016, Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V, Int. J. Parasitol. Drugs Drug Resist., 6, 220, 10.1016/j.ijpddr.2016.08.004 Palace-Berl, 2018, Investigating the structure-activity relationships of N’ -[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds, Eur. J. Med. Chem., 144, 29, 10.1016/j.ejmech.2017.12.011 Pérez-Molina, 2009, Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis, J. Antimicrob. Chemother., 64, 1139, 10.1093/jac/dkp357 Pérez-Molina, 2018, Chagas disease, Lancet, 391, 82, 10.1016/S0140-6736(17)31612-4 Pires, 2014, DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach, Nucleic Acids Res., 42, W314, 10.1093/nar/gku411 Prasad, 1996 Purkait, 2012, Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani, Antimicrob. Agents Chemother., 56, 1031, 10.1128/AAC.00030-11 Schrick, 2000, FACKEL is a sterol C-14 reductase required for organized cell division and expansion in Arabidopsis embryogenesis, Genes Dev., 14, 1471, 10.1101/gad.14.12.1471 Sekiya, 1983, Reorganization of membrane ergosterol during cell fission events of Candida albicans: a freeze-fracture study of distribution of filipin-ergosterol complexes, J. Ultrasruct. Res., 83, 48, 10.1016/S0022-5320(83)90064-3 Silva, 2016, Design, synthesis and antitrypanosomal activity of some nitrofurazone 1,2,4-triazolic bioisosteric analogues, Eur. J. Med. Chem., 121, 553, 10.1016/j.ejmech.2016.04.065 Soeiro, 2013, In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi, Antimicrob. Agents Chemother., 57, 4151, 10.1128/AAC.00070-13 Strushkevich, 2010, Structural basis of human CYP51 inhibition by antifungal azoles, J. Mol. Biol., 397, 1067, 10.1016/j.jmb.2010.01.075 Urbina, 2010, Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches, Acta Trop., 115, 55, 10.1016/j.actatropica.2009.10.023 Urbina, 2003, In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease, Int. J. Antimicrob. Agents, 21, 27, 10.1016/S0924-8579(02)00273-X Velazquez, 2015, Randomized trial of benznidazole for chronic Chagas' cardiomyopathy, N. Engl. J. Med., 373, 1295, 10.1056/NEJMoa1507574 Viotti, 2006, Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial, Ann. Intern. Med., 144, 724, 10.7326/0003-4819-144-10-200605160-00006 Warrilow, 2019, The evolution of azole resistance in Candida albicans sterol 14α-demethylase (CYP51) through incremental amino acid substitutions, Antimicrob. Agents Chemother., 63, 10.1128/AAC.02586-18 WHO, 2013 Wilkinson, 2008, A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes, Proc. Natl. Acad. Sci. U.S.A., 105, 5022, 10.1073/pnas.0711014105 Yardley, 1999, In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections, Am. J. Trop. Med. Hyg., 61, 193, 10.4269/ajtmh.1999.61.193 Yuan, 2012 Yun, 2009, Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières, PLoS Neglected Trop. Dis., 3, e488, 10.1371/journal.pntd.0000488 Zhang, 2019, The fungal CYP51s: their functions, structures, related drug resistance, and inhibitors, Front. Microbiol., 10, 691, 10.3389/fmicb.2019.00691 Zingales, 2015, A novel ABCG-like transporter of Trypanosoma cruzi is involved in natural resistance to benznidazole, Mem. Inst. Oswaldo Cruz, 110, 433, 10.1590/0074-02760140407